trastuzumab deruxtecan


( Last Updated : October 28, 2022)
Generic Name:
trastuzumab deruxtecan
Project Status:
Pending
Therapeutic Area:
unresectable or metastatic HER2-low breast cancer
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Enhertu
Project Line:
Reimbursement Review
Project Number:
PC0305-000
Call for patient/clinician input closed:
Tumour Type:
Breast

Details


Manufacturer Requested Reimbursement Criteria1:
​As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with HR+ breast cancer should additionally have received or be ineligible for endocrine therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer should additionally have received or be ineligible for endocrine therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.